Tlando Patent Expiration

Tlando is a drug owned by Verity Pharmaceuticals Inc. It is protected by 13 US drug patents filed from 2022 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2041. Details of Tlando's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11464735 Fixed dose oral testosterone undecanoate compositions and use thereof
Apr, 2041

(16 years from now)

Active
US12011503 Fixed dose oral testosterone undecanoate compositions and use thereof
Oct, 2040

(15 years from now)

Active
US11559530 Oral testosterone undecanoate therapy
Nov, 2037

(13 years from now)

Active
US9949985 High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

Active
US11311555 High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

Active
US11433083 High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

Active
US11364249 High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

Active
US10716794 High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

Active
US10226473 High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

Active
US9943527 High-strength testosterone undecanoate compositions
Nov, 2030

(6 years from now)

Active
US8778922 Steroidal compositions
Jan, 2029

(4 years from now)

Active
US11304960 Steroidal compositions
Jan, 2029

(4 years from now)

Active
US8865695 Steroidal compositions
Jan, 2029

(4 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tlando's patents.

Given below is the list of recent legal activities going on the following patents of Tlando.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 09 Mar, 2023 US10226473
Surcharge for late Payment, Small Entity 09 Mar, 2023 US10226473
Recordation of Patent Grant Mailed 24 Jan, 2023 US11559530
Patent Issue Date Used in PTA Calculation 24 Jan, 2023 US11559530
Correspondence Address Change 09 Jan, 2023 US11464735
Email Notification 05 Jan, 2023 US11559530
Issue Notification Mailed 04 Jan, 2023 US11559530
Mail Miscellaneous Communication to Applicant 28 Dec, 2022 US11559530
Email Notification 28 Dec, 2022 US11559530
Miscellaneous Communication to Applicant - No Action Count 22 Dec, 2022 US11559530


FDA has granted several exclusivities to Tlando. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Tlando, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Tlando.

Exclusivity Information

Tlando holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Tlando's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 28, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Tlando is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tlando's family patents as well as insights into ongoing legal events on those patents.

Tlando's Family Patents

Tlando has patent protection in a total of 15 countries. It has a significant patent presence in the US with 68.9% of its patents being US patents. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Tlando.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Tlando's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 28, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Tlando Generics:

There are no approved generic versions for Tlando as of now.

Alternative Brands for Tlando

Tlando which is used for treating conditions associated with low levels of testosterone in adult males., has several other brand drugs in the same treatment category and using the same active ingredient (Testosterone Undecanoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Endo Operations
Aveed

(uses Testosterone Undecanoate)

Used for treating conditions associated with deficiency or absence of endogenous testosterone in adult males, including primary hypogonadism and hypogonadotropic hypogonadism.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Testosterone Undecanoate. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Marius Pharms Llc
Kyzatrex
Tolmar
Jatenzo






About Tlando

Tlando is a drug owned by Verity Pharmaceuticals Inc. It is used for treating conditions associated with low levels of testosterone in adult males. Tlando uses Testosterone Undecanoate as an active ingredient. Tlando was launched by Verity in 2022.

Approval Date:

Tlando was approved by FDA for market use on 28 March, 2022.

Active Ingredient:

Tlando uses Testosterone Undecanoate as the active ingredient. Check out other Drugs and Companies using Testosterone Undecanoate ingredient

Treatment:

Tlando is used for treating conditions associated with low levels of testosterone in adult males.

Dosage:

Tlando is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
112.5MG CAPSULE Prescription ORAL